Sapio Sciences, the science-awareTM AI lab informatics platform, announced that the Wellcome Sanger Institute has selected the Sapio Informatics Platform as its central LIMS to underpin the...

Medra, the company developing the first platform for Physical AI Scientists, announced a $52 million Series A financing led by Human Capital, with participation from existing investors Lux Capital,...

Servier, an independent international pharmaceutical group governed by a foundation, announced that Voranigo® (vorasidenib) has been awarded the inaugural 2025 Prix Galien Bridges Award for Best...

FIZE Medical Inc., a leader in smart fluid management solutions for critically ill patients, announced an exclusive distribution agreement with Asahi Kasei Medical Co., Ltd. to launch the FIZE kUO®...

Just a few months after the world’s first Gastric Mucosal Ablation (GMA) case using MOVIVA® at the Policlinico Universitario Agostino Gemelli in Rome, clinical experience is rapidly expanding across...

This growth is particularly remarkable considering that Re2O had relatively low brand recognition only six months ago. Dermatology and plastic surgery clinics, as well as major university hospitals...

Celltrion, Inc. announced that Health Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications...

Samsung Bioepis Co., Ltd. announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially...

The Menarini Group a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing...

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced that Eisai has completed the rolling submission of...

VahatiCor, a medtech company transforming cardiac care for Coronary Microvascular Dysfunction (CMD), announced the successful closing of its $23 million Series B financing led by S3 Ventures, with...

Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce...